MCL1 and plasma cell myeloma: Studies employing genetic silencing or inducible expression of ligands that inhibit MCL-1 demonstrate its essentiality in the growth of multiple tumor types including multiple myeloma (MM)15, AML16, and non-Hodgkin lymphoma17.